CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls

International Journal of Cancer

Volumn 104, Issue 5, 2003, Pages 650-657

  Vineis, Paolo ^a   Veglia, Fabrizio ^b   Benhamou, Simone ^c   Butkiewicz, Dorota ^d   Cascorbi, Ingolf ^e   Clapper, Margie L ^f   Dolzan, Vita ^g   Haugen, Aage ^h   Hirvonen, Ari ⁱ   Ingelman Sundberg, Magnus ^j   Kihara, Masahiro ^k   Kiyohara, Chikako ^l   Kremers, Pierre ^m   Le Marchand, Loic ⁿ   Ohshima, Susumu ^o   Pastorelli, Roberta ^p   Rannug, Agneta ^j   Romkes, Marjorie ^q   Schoket, Bernadette ^r   Shields, Peter ^s   Strange, Richard C ^t   Stucker, Isabelle ^u   Sugimura, Haruhiko ^v   Garte, Seymour ^w   Gaspari, Laura ^x   Taioli, Emanuela ^x   more..

^a UNIVERSITY OF TURIN   (Italy)

^b ISI FOUNDATION   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF LJUBLJANA   (Slovenia)

^h NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

ⁱ FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^j KAROLINSKA INSTITUTE   (Sweden)

^k KANAGAWA CANCER CENTER   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

^m UNIVERSITY OF LIÈGE   (Belgium)

ⁿ UNIVERSITY OF HAWAII   (United States)

^o SAITAMA MEDICAL UNIVERSITY   (Japan)

^p MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^q UNIVERSITY OF PITTSBURGH   (United States)

^r NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

^s GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^t KEELE UNIVERSITY   (United Kingdom)

^u Unite de Recherche Epidemiologiques   (France)

^v HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^w Genetics Research Institute   (Italy)

^x FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

CYP1A1T3801C polymorphism; Lung cancer

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450 1A1;

ADENOCARCINOMA; ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; AGE; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; RACE; RISK FACTOR; SEXUAL DEVELOPMENT; SMOKING; TIME;

AGE FACTORS; CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP1A1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, GENETIC; RISK FACTORS; SEX CHARACTERISTICS; SMOKING; TIME FACTORS;

EID: 0037400385     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10995     Document Type: Article

References (33)

1. Vineis P, Caporaso N, Cuzick J, Lang M, Malats N, Boffetta P. Genetic susceptibility to cancer: metabolic polymorphisms. IARC Scientific Publication No. 148. Lyon: International Agency for Research on Cancer, 1999.
2. Kellermann G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 1973;289:934-7.
3. Smart J, Daly AK. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000;10:11-24
4. Taioli E. International collaborative study on genetic susceptibility to environmental carcinogens. Cancer Epidemiol Biomarkers Prev 199;8:727-8.
5. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2000;10:1239-48.
6. Garte S, Boffetta P, Caporaso N, Vineis P. Metabolic gene allele nomenclature. Cancer Epidemiol Biomarkers Prev 2000;10:1305-6.
7. Houlston RS. CYP1A1 polymorphisms and lung cancer risk: a metaanalysis. Pharmacogenetics 2000;10:105-14.
8. Breslow N, Day N. Statistical methods in cancer cresearch. Vol I. The analysis of case control studies. IARC Scientific Publication No. 32, Lyon: International Agency for Research on Cancer, 1980,
9. Cascorbi I, Brockmöller J, Roots IA. C4887 A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-9.
10. Dolzan V, Rufolf Z, Breskvar K. Genetic polymorphism of xenobiotic metabolising enzymes in Slovenian lung cancer patients. Pflugers Arch 2000;439(suppl 3):R29-30.
11. Hirvonen A, Husgafvel-Pursianen K, Karjalainen A, Anttila S, Vainio H. Point-mutational MspI and Ile-Vapolymorphism closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1992;1:485-9.
12. Kihara M, Kihara M, Noda K. Risk of smoking for squamous and small cell carcinoma of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphism in a Japanese population. Carcinogenesis 1995;16:2331-6.
13. Jacquet M, Lambert V, Baudoux E, Muller M, Kremers P, Gielen J. Correlation between P450 CYP1A1 inducibility, Mspi genotype and lung cancer incidence. Eur J Cancer 1996;32A:1701-6.
14. Alexandrie A, Ingelman-Sundberg M, Seidegard J, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and historical cancer type. Carcinogenesis 1994;15:1785-90.
15. Shields PG, Caporaso NE, Falk RT, Sugimura H, Trivers GE, Trump BF, Hoover RN, Weston A, Harris C. Lung cancer, race and CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 1993;2:481-5.
16. Stucker I, Jacquet M, De Waziers I, Cénée S, Beaume P, Kremers P, Hémon D. Relation between inducibility of CYP1A1, GSTM1 and lung cancer in a French population. Pharmacogenetics 2000;10:617-27.
17. Sugimura H, Wakai K, Genka K, Nagura K, Igarashi H, Nagayama K, Ohkawa A, Baba S, Morris BJ, Tsugane S, Ohno Y, Gao C, et al. Association of Ile462Val(exon 7) polymorphism of cytochrome P450 1A1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev 1998;7:413-7.
18. Persson I, Johansson I, Lou Y, Yue Q, Duan L, Bertilsson L, Ingelman-Sundberg M. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 1999;81:325-329.
19. Le Marchand L, Sivaraman L, Pierce L, Seifried A, Lum A, Wilkens LR, Lau AF. Association of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998;58:4858-63.
20. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte SJ. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis 1998;19:813-817.
21. Bouchardy C, Wikman H, Benhamou S, Hirvonen A, Dayer P, Husgafvel-Pursiainen K. CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers 1997;2:131-134.
22. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000;30:153-160.
23. I450) gene: lack of association and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991;1:20-25.
24. Pastorelli R, Guanci M, Cerri A, Negri E, La Vecchia C, Fumagalli F, Mezzetti M, Cappelli R, Panigalli T, Fanelli R, Airoldi L. Impact of inherited polymorphisms in glutathione S-transferase M 1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 1998;7:703-709.
25. Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S, Hirohata T. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 1998;8:315-323.
26. Oshima S, Xu Y. p53 gene mutations, and CYP1A1 and GSTM1 genotypes in pulmonary squamous cell carcinomas. Mol Pathol 1997;50:108-110.
27. Schoket B, Phillips DH, Kostic S, Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 Msp1 and GSTM1 genotypes in lung patients. Carcinogenesis 1998;19:841-846.
28. Butkiewicz D, Cole KJ, Phillips DH, Harris CC, Chorazy M. GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adducts levels. Eur J Cancer Prev 1999;8:315-323.
29. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 1993;53:2994-9.
30. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4:242-6.
31. Merlo F, Andreassen A, Weston A, Pan C-F, Haugen A, Valerio F, Reggiardo G, Fontana V, Garte S, Puntoni R, Abbondandolo A. Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of polycyclic aromatic hydrocarbons. Cancer Epidemiol Biomarkers Prev 1998;7:147-155.
32. Wu M-T, Huang S-L, Ho C-K, Yeh Y-F, Christiani DC. Cytochrome P450 1A1 MspI polymorphism and urinary 1-hydroxypyrene concentrations in coke-oven workers. Cancer Epidemiol Biomarkers Prev 1998;7:823-829.
33. Nerurkar PV, Okinaka L, Aoki C, Seifried A, Lum-Jones A, Wilkens LR, Le Marchand L. CYP1A1, GSTM1, and GSTP1 genetic polymorphisms and urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 2000;9:1119-22.